BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fidaxomicin: Final Phase III data

Previously reported data from a double-blind, North American Phase III trial of fidaxomicin to treat CDI in 629 patients were published in the New England Journal of Medicine. The data showed that fidaxomicin met the primary and secondary endpoints of non-inferiority to Vancocin vancomycin in clinical cure rate and CDI recurrence,...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >